Raymond James Financial I... (RJF)
Bid | 165.14 |
Market Cap | 32.96B |
Revenue (ttm) | 15.57B |
Net Income (ttm) | 2.13B |
EPS (ttm) | 10.21 |
PE Ratio (ttm) | 16.19 |
Forward PE | 14.13 |
Analyst | Hold |
Ask | 165.39 |
Volume | 64,139 |
Avg. Volume (20D) | 1,090,258 |
Open | 164.02 |
Previous Close | 164.36 |
Day's Range | 163.46 - 165.50 |
52-Week Range | 113.91 - 174.32 |
Beta | 1.06 |
Analyst Forecast
According to 0 analyst ratings, the average rating for RJF stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

2 weeks ago · https://thefly.com
Palvella Therapeutics initiated with an Outperform at Raymond JamesRaymond James initiated coverage of Palvella Therapeutics with an Outperform rating and $54 price target. The firm says the company is developing Qtorin rapamycin, a novel topical therapy designed to ...

3 weeks ago · seekingalpha.com
Raymond James: Rising Markets Offset Cash Headwinds (Rating Upgrade)Raymond James Financial's fundamentals remain strong, with higher AUM and resilient net interest income despite recent earnings noise from a one-time legal reserve. Client cash outflows and potential ...

3 weeks ago · fool.com
Raymond James Posts 5 Percent Q3 GainRaymond James Posts 5 Percent Q3 Gain

3 weeks ago · seekingalpha.com
Raymond James Financial, Inc. (RJF) Q3 2025 Earnings Call TranscriptRaymond James Financial, Inc. (NYSE:RJF ) Q3 2025 Earnings Conference Call July 23, 2025 5:00 PM ET Company Participants Jonathan W. Oorlog - Senior VP, CFO & Controller Kristina Waugh - Senior Vice P...